Structure Therapeutics (GPCR) CCO John Berrios Receives RSU Award

What Happened
John Joseph Berrios, Chief Commercial Officer of Structure Therapeutics, was granted two awards on August 6, 2026: 140,766 ordinary-share RSUs and 174,612 RSU-type derivative awards (total 315,378). Both were reported as acquisitions (transaction code A) at $0.00 per share (no cash paid). These are awards/contingent rights to receive ordinary shares over time, not open-market purchases or sales.

Key Details

• Transaction date: August 6, 2026; Form 4 filed August 7, 2026 (timely filing).
• Consideration: $0.00 per share (awarded, not purchased or sold).
• Grant totals: 140,766 shares (ordinary RSUs) + 174,612 derivative RSUs = 315,378 total units.
• Vesting (per footnotes): one award vests 1/4 annually on each anniversary of Aug 6, 2026; the other vests 1/4 on the first anniversary of Aug 6, 2026 with the remainder in 36 equal monthly installments thereafter (both subject to continued service).
• ADS note: Ordinary shares may be represented by ADSs (1 ADS = 3 ordinary shares) — relevant when comparing to ADS market prices.
• Shares owned after transaction: not specified in the filing.
• Transaction type: Award/Grant (A). No sale or cash exercise occurred.

Context
RSUs and derivative RSU awards are long-term compensation that convert to ordinary shares only as they vest (they are contingent, not immediately tradable shares). These grants are routine executive compensation and do not indicate immediate buying or selling of stock.